Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

· Histologically- or cytologically-confirmed diagnosis of stage IIIB or IV Non-Small Cell Lung Cancer · Received only one prior treatment (not including radiation) · Measurable disease per Response Evaluation Criteria in Solid Tumors Group (RECIST) guidelines · Life expectancy of ≥ 4 months · Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 · Adequate hematologic, renal and hepatic function · Serum-fasting cholesterol ≤ 300 mg/dL Serum-fasting triglycerides ≤ 2.5 X ULN

· Brain metastases requiring treatment · History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline · Systemic chemotherapy, radiotherapy, hormonal therapy or immunotherapy within 30 days before enrollment · Prior epidermal growth factor receptor targeting agents with the exception of the small molecule EGFr tyrosine kinase inhibitors · Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short serum half-life (less than 1 week) within 30 days before enrollment, or prior experimental or approved proteins/antibodies with longer serum half-life within 6 weeks before enrollment · Prior therapy with sirolimus, sirolimus analogs · Immunosuppressive agents within 28 days before enrollment